Literature DB >> 10469434

Plexiform neurofibromas.

B R Korf1.   

Abstract

Plexiform neurofibromas are among the most common and debilitating complications of neurofibromatosis type 1 (NF1). They account for substantial morbidity, including disfigurement, functional impairment, and may even be life threatening. Plexiform neurofibromas are also subject to transformation into malignant peripheral nerve sheath tumor (MPNST), a complication that is refractory to treatment both because of a paucity of effective therapies for malignant soft tissue sarcomas in general, and because of the delay in diagnosis that results from change of a small portion of a large pre-existing tumor. The current mainstay of treatment of plexiform neurofibromas, and of MPNST for that matter, is surgical resection. The major variables are the timing and means of identification of plexiform neurofibromas, methods of follow-up, and indications for surgery. There is no established means of medical treatment, but research into the molecular pathogenesis of NF1, as well as advances in tumor therapy in general, are opening the way towards clinical trials for plexiform neurofibroma. Am. J. Med. Genet. (Semin. Med. Genet.) 89:31-37, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10469434     DOI: 10.1002/(sici)1096-8628(19990326)89:1<31::aid-ajmg7>3.0.co;2-w

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  99 in total

1.  [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.

Authors:  L L Tsai; L Drubach; F Fahey; M Irons; S Voss; N J Ullrich
Journal:  J Neurooncol       Date:  2012-03-11       Impact factor: 4.130

2.  Von recklinghausens disease: a series of four cases with variable expression.

Authors:  K P Arun; P Thomas Joseph; H P Jaishankar; M S Abhinethra
Journal:  J Maxillofac Oral Surg       Date:  2013-02-07

Review 3.  MR imaging of abdominopelvic involvement in neurofibromatosis type 1: a review of 43 patients.

Authors:  T Thomas Zacharia; Diego Jaramillo; Tina Young Poussaint; Bruce Korf
Journal:  Pediatr Radiol       Date:  2004-10-27

4.  CT features of plexiform neurofibroma of the submandibular gland.

Authors:  M Aribandi; W E Wood; D M Elston; D L Weiss
Journal:  AJNR Am J Neuroradiol       Date:  2006-01       Impact factor: 3.825

5.  MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1.

Authors:  V F Mautner; M Hartmann; L Kluwe; R E Friedrich; C Fünsterer
Journal:  Neuroradiology       Date:  2006-01-24       Impact factor: 2.804

6.  Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.

Authors:  Urania Dagalakis; Maya Lodish; Eva Dombi; Ninet Sinaii; Jessica Sabo; Andrea Baldwin; Seth M Steinberg; Constantine A Stratakis; Brigitte C Widemann
Journal:  J Pediatr       Date:  2013-12-08       Impact factor: 4.406

7.  Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma.

Authors:  Jianqiang Wu; Jason T Crimmins; Kelly R Monk; Jon P Williams; Maureen E Fitzgerald; Susan Tedesco; Nancy Ratner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

8.  18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.

Authors:  Johannes Salamon; Simon Veldhoen; Ivayla Apostolova; Peter Bannas; Jin Yamamura; Jochen Herrmann; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner; Thorsten Derlin
Journal:  Eur Radiol       Date:  2013-10-05       Impact factor: 5.315

9.  Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.

Authors:  Scott R Plotkin; Stephanie D Davis; Kent A Robertson; Srivandana Akshintala; Julian Allen; Michael J Fisher; Jaishri O Blakeley; Brigitte C Widemann; Rosalie E Ferner; Carole L Marcus
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

Review 10.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.